What changed in this filing

/stocks — the workspaceLOADING

Item 2. Unregistered Sales of Equity Securities

2022-08-12 compared with 2022-05-13 · 65 added, 63 removed, 7 unchanged (95% of the section changed)

2 unchanged sentences

Use of Proceeds

In February 2021, our Sponsor paid $25,000, or

approximately $0.003 per share, to cover certain of our offering costs in exchange for 7,187,500 Founder Shares.

Subsequently on March

5, 2021, we effected a 1.2 to 1 share recapitalization with respect to our Class B ordinary shares, as a result of which our Sponsor

held 8,625,000 Founder Shares.

The number of Founder Shares outstanding was determined based on the expectation that the total size of

our Public Offering would be a maximum of 34,500,000 Units if the underwriters’ over-allotment option is exercised in full and

therefore that such Founder Shares would represent 20% of the outstanding shares after the Public Offering.

Up to 1,125,000 of these

shares were subject to surrender for no consideration depending on the extent to which the underwriter’s over-allotment was exercised.

On October 29, 2021, as a result of the partial exercise of the over-allotment option, our Sponsor forfeited 381,250 Founder Shares and

the remaining Founder Shares are no longer subject to forfeiture.

Such securities were issued in connection with our organization pursuant

to the exemption from registration contained in Section 4(a)(2) of the Securities Act.

No underwriting discounts or commissions were

paid with respect to such sales.

On September 24, 2021, we consummated the IPO

of 30,000,000 Units at $10.00 per Unit.

Each Unit consists of one Class A ordinary share, and one-half of one Public Warrant, with each

whole warrant entitling the holder to purchase one Class A ordinary share for $11.50 per share, subject to adjustment.

The underwriters

had a 45-day option to purchase up to an additional 4,500,000 Units to cover over-allotments, if any.

On October 29, 2021, the underwriters

partially exercised the over-allotment option and purchased 2,975,000 Over-Allotment Units, generating additional gross proceeds of $29,750,000,

and forfeited their option to purchase the remaining 1,535,000 Units.

The securities in the Public Offering were registered under the

Securities Act on a registration statement on Form S-1 (No.

The SEC declared the registration statement effective on September

Simultaneously with the closing of the IPO, we

consummated the sale of 6,250,000 Private Placement Warrants to our Sponsor at a price of $1.00 per Private Placement Warrant, generating

total gross proceeds of $6,250,000.

On October 29, 2021, simultaneously with the closing of the Over-Allotment, our Sponsor purchased

an additional 595,000 Private Placement Warrants at a price of $1.00 per Private Placement Warrant, generating aggregate gross proceeds

Such securities were issued pursuant to the exemption from registration contained in Section 4(a)(2) of the Securities Act.

In February 2021, our

Sponsor paid $25,000, or approximately $0.003 per share, to cover certain of our offering costs in exchange for 7,187,500 Founder Shares.

Subsequently on March 5, 2021, we effected a 1.2 to 1 share recapitalization with respect to our Class B ordinary shares, as a result

of which our Sponsor held 8,625,000 Founder Shares.

The number of Founder Shares outstanding was determined based on the expectation that

the total size of our Public Offering would be a maximum of 34,500,000 Units if the underwriters’ over-allotment option is exercised

in full and therefore that such Founder Shares would represent 20% of the outstanding shares after the Public Offering.

Up to 1,125,000

of these shares were subject to surrender for no consideration depending on the extent to which the underwriter’s over-allotment

was exercised.

On October 29, 2021, as a result of the partial exercise of the over-allotment option, our Sponsor forfeited 381,250 Founder

Shares and the remaining Founder Shares are no longer subject to forfeiture.

Such securities were issued in connection with our organization

pursuant to the exemption from registration contained in Section 4(a)(2) of the Securities Act.

No underwriting discounts or commissions

were paid with respect to such sales.

On September 24, 2021,

we consummated the IPO of 30,000,000 Units at $10.00 per Unit.

Each Unit consists of one Class A ordinary share, and one-half of one Public

Warrant, with each whole warrant entitling the holder to purchase one Class A ordinary share for $11.50 per share, subject to adjustment.

The underwriters had a 45-day option to purchase up to an additional 4,500,000 Units to cover over-allotments, if any.

On October 29,

2021, the underwriters partially exercised the over-allotment option and purchased 2,975,000 Over-Allotment Units, generating additional

gross proceeds of $29,750,000, and forfeited their option to purchase the remaining 1,535,000 Units.

The securities in the Public Offering

were registered under the Securities Act on a registration statement on Form S-1 (No.

The SEC declared the registration statement

effective on September 21, 2021.

Simultaneously with the

closing of the IPO, we consummated the sale of 6,250,000 Private Placement Warrants to our Sponsor at a price of $1.00 per Private Placement

Warrant, generating total gross proceeds of $6,250,000.

On October 29, 2021, simultaneously with the closing of the Over-Allotment, our

Sponsor purchased an additional 595,000 Private Placement Warrants at a price of $1.00 per Private Placement Warrant, generating aggregate

gross proceeds of $595,000.

Such securities were issued pursuant to the exemption from registration contained in Section 4(a)(2) of the

Securities Act.

No underwriting discounts or commissions were paid with respect to such sales.

We paid a total of $16,908,188 in underwriting

discounts and commissions and offering costs, consisting of $4,595,000 of underwriting commissions, $11,541,250 of deferred underwriting

commissions, and $771,938 of other offering costs related to the IPO.

There has been no material change in the planned

use of the proceeds from the Public Offering and the sale of the Private Placement Warrants as is described in the IPO Prospectus.

In connection with the consummation of the IPO,

we entered into a forward purchase agreement with Kingstown 1740 Fund, LP and Kingfishers L.P., affiliates of Kingstown Capital Partners,

LLC, collectively “Kingstown” and our Sponsor, pursuant to which Kingstown agreed that it will purchase from us up to 5,000,000

Forward Purchase Shares, for $10.00 per share, or an aggregate amount of up to $50,000,000, in a private placement that will close concurrently

with the closing of our initial Business Combination.

The proceeds from the sale of these Forward Purchase Shares, together with the

amounts available to us from the Trust Account (after giving effect to any redemptions of Public Shares) and any other equity or debt

financing obtained by us in connection with the Business Combination, will be used to satisfy the cash requirements of the Business Combination,

including funding the purchase price and paying expenses and retaining specified amounts to be used by the post-Business Combination

company for working capital or other purposes.

To the extent that the amounts available from the Trust Account and other financing are

sufficient for such cash requirements, Kingstown may purchase less than 5,000,000 Forward Purchase Shares.

In addition, Kingstown’s

commitment under the forward purchase agreement will be subject to approval of its investment committee prior to the closing of our initial

Business Combination.

Accordingly, if Kingstown’s investment committee does not give its approval, Kingstown will not be obligated

to purchase the Forward Purchase Shares.

Further, we have the right, in our sole discretion, to reduce the amount of Forward Purchase

Shares that Kingstown may purchase pursuant to the forward purchase agreement.

Pursuant to the terms of the forward purchase agreement,

Kingstown will have the option to assign its commitment to one of its affiliates and up to $5,000,000 to members of our management team

or board of directors.

The Forward Purchase Shares will be identical to the Class A ordinary shares included in the Units sold in the

Public Offering, except that they will be subject to transfer restrictions and registration rights.

We paid a total of $16,908,188

in underwriting discounts and commissions and offering costs, consisting of $4,595,000 of underwriting commissions, $11,541,250 of deferred

underwriting commissions, and $771,938 of other offering costs related to the IPO.

There has been no material

change in the planned use of the proceeds from the Public Offering and the sale of the Private Placement Warrants as is described in the

IPO Prospectus.

In connection with the

consummation of the IPO, we entered into a forward purchase agreement with Kingstown 1740 Fund, LP and Kingfishers L.P., affiliates of

Kingstown Capital Partners, LLC, collectively “Kingstown” and our Sponsor, pursuant to which Kingstown agreed that it will

purchase from us up to 5,000,000 Forward Purchase Shares, for $10.00 per share, or an aggregate amount of up to $50,000,000, in a private

placement that will close concurrently with the closing of our initial Business Combination.

The proceeds from the sale of these Forward

Purchase Shares, together with the amounts available to us from the Trust Account (after giving effect to any redemptions of Public Shares)

and any other equity or debt financing obtained by us in connection with the Business Combination, will be used to satisfy the cash requirements

of the Business Combination, including funding the purchase price and paying expenses and retaining specified amounts to be used by the

post-Business Combination company for working capital or other purposes.

To the extent that the amounts available from the Trust

Account and other financing are sufficient for such cash requirements, Kingstown may purchase less than 5,000,000 Forward Purchase Shares.

In addition, Kingstown’s commitment under the forward purchase agreement will be subject to approval of its investment committee

prior to the closing of our initial Business Combination.

Accordingly, if Kingstown’s investment committee does not give its approval,

Kingstown will not be obligated to purchase the Forward Purchase Shares.

Further, we have the right, in our sole discretion, to reduce

the amount of Forward Purchase Shares that Kingstown may purchase pursuant to the forward purchase agreement.

Pursuant to the terms of

the forward purchase agreement, Kingstown will have the option to assign its commitment to one of its affiliates and up to $5,000,000

to members of our management team or board of directors.

The Forward Purchase Shares will be identical to the Class A ordinary shares

included in the Units sold in the Public Offering, except that they will be subject to transfer restrictions and registration rights.

Defaults Upon Senior Securities.

2 unchanged sentences

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-Q

Item 2. Unregistered Sales of Equity Securities